Co-Founder, Day One Biopharmaceuticals
Appears in 1 story
Retired from Day One in late 2024; joined Pediatric Brain Tumor Foundation board
For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the Food and Drug Administration (FDA) cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Now the company behind it, Day One Biopharmaceuticals, has agreed to be acquired by France's Servier for $2.5 billion in cash, a 68% premium over its previous closing share price.
Updated Mar 6
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
